Of eight weeks, closes patient enrollment in the Phase II study of Topical Interferon Alpha – 2b in patients with ano – genital warts – Helix BioPharma Corp. announced that its Phase II trial of Topical Interferon Alpha – 2b for the treatment of anogenital warts has completed patient enrollment, with the required 120th Patients randomized to to enter the trial. www.erectalis.net/erectalis-vs-viagra.html

This is a major milestone for Helix ‘s Topical Interferon Alpha-2b clinical program, said John Docherty, president and COO of Helix BioPharma. Our efforts in the recruitment rate in recent months to increase have been successful, and we look forward to receiving the results of the study, when all patients have completed procedures and analyzes. .

Trouble with walking is any of the most debilitating problems of the people with MS face of, said Russell Katz, Director of Neurology Department items to FDA Center for Drug Evaluation and Research.

www.erectalis.net